Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Biotechs Of Japan Follow SC World In Research Work With Academics

This article was originally published in PharmAsia News

Executive Summary

Japanese biotechs seek to take advantage of a new demand for influenza drugs within and without Japan

Japanese biotechs seek to take advantage of a new demand for influenza drugs within and without Japan.

SC World is working with academic institutions to research antibodies to block the flu after symptoms have developed. Unlike other leading treatments, SC World relies on a proprietary method to develop an antibody aimed at treating patients after symptoms have developed. KinoPharma is developing a drug to help viruses to grow using human enzymes to fight flu viruses even after they have mutated. (Click here for more - a subscription may be required)

"More Japan Bioventures Take On Flu Drug Development" - Nikkei (japan) (1/19/10)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC073053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By